ABSI — Absci Corp

Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1672688 ·
Last close
$5.28
Market Cap
$823.18M
52W High
$6.72
52W Low
$2.24
ADV30
4,945,606
Next earnings
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 215,000 -30,846,000 -29,599,000 195,593,000 8,627,000 23,622,000
Dec 2025 650,000 -36,142,000 -29,562,000 216,297,000 20,025,000 26,848,000
Sep 2025 378,000 -30,154,000 -28,706,000 244,992,000 9,476,000 34,652,000
Jun 2025 593,000 -31,393,000 -30,569,000 209,892,000 38,024,000 36,519,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-92,925,000
Investing CF
$-50,160,000
Financing CF
$105,949,000
CapEx
$-1,233,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.85
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-624,784,000
Inventory
Receivables
$1,000,000
ST Investments
$124,267,000
EBIT TTM
$-114,905,000
Pretax Income TTM
$-115,114,000
Interest Exp TTM
$209,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,836,000
EBITDA
$-116,437,000
Free Cash Flow
$-41,475,376
Enterprise Value
$700,329,664
Total Cash
$125,705,000
Total Debt
$4,415,000
Shares Out
155,905,056
Trailing EPS
$-0.82
Book Value
$1.11
ROE
-63.9%
ROA
-37.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,800,000 -125,418,000 -115,183,000 216,297,000 26,848,000 -92,925,000
Dec 2024 4,534,000 -108,888,000 -103,106,000 213,608,000 34,475,000 -72,402,000
Dec 2023 5,718,000 -94,180,000 -110,566,000 217,298,000 41,122,000 -64,636,000
Dec 2022 5,747,000 -106,750,000 -104,904,000 321,008,000 46,594,000 -81,339,000

TTM Snapshot

Revenues TTM
$1,701,000
NetIncome TTM
$-27,398,000
OpCashFlow TTM
$0
Assets (Latest)
$213,608,000
Forward EPS
$-0.62

Peers — same industry

TickerNameMarket CapLastDaily %
QDEL QuidelOrtho Corp $817.61M $11.99
ACHV ACHIEVE LIFE SCIENCES, INC. $468.13M $4.56
NNNN Anbio Biotechnology $1.45B $33.01
NRC NRC HEALTH $429.10M $19.04
NTLA Intellia Therapeutics, Inc. $1.76B $12.61

News headlines (Yahoo Finance, 1h cache)

The 1 AI Stock I'd Put in a Time Capsule and Open in 2036
2026-05-26 02:20 · Yahoo
Absci Insider Buyers Pleased With US$700k Return On Investment
2026-05-20 19:24 · Yahoo
Absci to Participate in Upcoming Investor Conferences
2026-05-20 12:00 · Yahoo
Marvell Stock Climbs After AMD Reveals Surprise Stake
2026-05-13 15:11 · Yahoo
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
2026-05-08 02:25 · Yahoo
Absci (ABSI) Q1 2026 Earnings Call Transcript
2026-05-07 22:50 · Yahoo
Absci Q1 Earnings Call Highlights
2026-05-07 22:39 · Yahoo
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
2026-05-07 20:05 · Yahoo
Recursion Pharmaceuticals Q1 Earnings Call Highlights
2026-05-06 20:42 · Yahoo
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-05 00:11 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.